Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
18 hedge funds and large institutions have $47.5M invested in Verona Pharma in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
6% more funds holding
Funds holding: 17 → 18 (+1)
0.14% less ownership
Funds ownership: 7.15% → 7.01% (-0.14%)
32% less capital invested
Capital invested by funds: $70.1M → $47.5M (-$22.6M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
+$113K |
| 2 |
Renaissance Technologies
New York
|
+$76.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$70.5K |
| 4 |
WS
Wedbush Securities
Los Angeles,
California
|
+$69.5K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$35.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$1.99M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$495 |
VRNA Hedge Fund Activity: Q1 2019 in Review
18 of the 4,624 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q1 2019, worth a combined $47.5M — down 32% from $70.1M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new VRNA positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was IHT Wealth Management, opening a new position worth an estimated $113K. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $1.99M sold.
- 18 institutional investors held Verona Pharma (VRNA) as of Q1 2019, up from 17 in Q4 2018.
- Funds reported $47.5M of Verona Pharma stock for Q1 2019, down 32% quarter-over-quarter.
- 3 funds opened new Verona Pharma positions in Q1 2019 and 2 closed out, a net change of +1 holder.
- The largest Verona Pharma buyer in Q1 2019 was IHT Wealth Management, an estimated $113K added.
- The largest Verona Pharma seller in Q1 2019 was Foresite Capital Management III, an estimated $1.99M sold.
Based on aggregated 13F filings for Q1 2019.